# Amgen Inc: financial statements, quarterly

AMGN · Nasdaq · CIK 318154 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amgn.md) · [Financials](/companies/amgn/financials.md) · [Filings](/companies/amgn/filings.md) · [Insiders](/companies/amgn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amgn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [6.9](/filings/0000318154-24-000044.md) | [8.2 d](/filings/0000318154-26-000010.md) | [7.4](/filings/0000318154-25-000020.md) | [8.4](/filings/0000318154-25-000056.md) | [8.5](/filings/0000318154-25-000072.md) | [9.1 d](/filings/0000318154-26-000010.md) | [8.1](/filings/0000318154-26-000057.md) | [9.2](/filings/0000318154-26-000126.md) | [9.6](/filings/0000318154-25-000072.md) | [9.9 d](/filings/0000318154-26-000010.md) | [8.6](/filings/0000318154-26-000057.md) | [10.1](/filings/0000318154-26-000126.md) |
| Cost of revenue | $bn | [1.8](/filings/0000318154-24-000044.md) | [3.1 d](/filings/0000318154-26-000010.md) | [3.2](/filings/0000318154-25-000020.md) | [3.2](/filings/0000318154-25-000056.md) | [3.3](/filings/0000318154-25-000072.md) | [3.1 d](/filings/0000318154-26-000010.md) | [3.0](/filings/0000318154-26-000057.md) | [3.0](/filings/0000318154-26-000126.md) | [3.1](/filings/0000318154-25-000072.md) | [3.0 d](/filings/0000318154-26-000010.md) | [2.7](/filings/0000318154-26-000057.md) | [2.8](/filings/0000318154-26-000126.md) |
| Gross profit | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $bn | [1.4](/filings/0000318154-24-000044.md) | [2.3 d](/filings/0000318154-26-000010.md) | [1.8](/filings/0000318154-25-000020.md) | [1.8](/filings/0000318154-25-000056.md) | [1.6](/filings/0000318154-25-000072.md) | [1.9 d](/filings/0000318154-26-000010.md) | [1.7](/filings/0000318154-26-000057.md) | [1.7](/filings/0000318154-26-000126.md) | [1.7](/filings/0000318154-25-000072.md) | [2.0 d](/filings/0000318154-26-000010.md) | [1.6](/filings/0000318154-26-000057.md) | [1.7](/filings/0000318154-26-000126.md) |
| Operating income | $bn | [2.0](/filings/0000318154-24-000044.md) | [1.3 d](/filings/0000318154-26-000010.md) | [1.0](/filings/0000318154-25-000020.md) | [1.9](/filings/0000318154-25-000056.md) | [2.0](/filings/0000318154-25-000072.md) | [2.3 d](/filings/0000318154-26-000010.md) | [1.2](/filings/0000318154-26-000057.md) | [2.7](/filings/0000318154-26-000126.md) | [2.5](/filings/0000318154-25-000072.md) | [2.7 d](/filings/0000318154-26-000010.md) | [2.7](/filings/0000318154-26-000057.md) | [3.5](/filings/0000318154-26-000126.md) |
| Income tax | $bn | [0.2](/filings/0000318154-24-000044.md) | [0.1 d](/filings/0000318154-26-000010.md) | [0.0](/filings/0000318154-25-000020.md) | [0.0](/filings/0000318154-25-000056.md) | [0.3](/filings/0000318154-25-000072.md) | [0.2 d](/filings/0000318154-26-000010.md) | [0.2](/filings/0000318154-26-000057.md) | [0.1](/filings/0000318154-26-000126.md) | [0.7](/filings/0000318154-25-000072.md) | [0.2 d](/filings/0000318154-26-000010.md) | [0.3](/filings/0000318154-26-000057.md) | [0.4](/filings/0000318154-26-000126.md) |
| Net income | $bn | [1.7](/filings/0000318154-24-000044.md) | [0.8 d](/filings/0000318154-26-000010.md) | [(0.1)](/filings/0000318154-25-000020.md) | [0.7](/filings/0000318154-25-000056.md) | [2.8](/filings/0000318154-25-000072.md) | [0.6 d](/filings/0000318154-26-000010.md) | [1.7](/filings/0000318154-26-000057.md) | [1.4](/filings/0000318154-26-000126.md) | [3.2](/filings/0000318154-25-000072.md) | [1.3 d](/filings/0000318154-26-000010.md) | [1.8](/filings/0000318154-26-000057.md) | [2.4](/filings/0000318154-26-000126.md) |
| Diluted EPS | $ per share | [3.22](/filings/0000318154-24-000044.md) | not reported | [(0.21)](/filings/0000318154-25-000020.md) | [1.38](/filings/0000318154-25-000056.md) | [5.22](/filings/0000318154-25-000072.md) | not reported | [3.20](/filings/0000318154-26-000057.md) | [2.65](/filings/0000318154-26-000126.md) | [5.93](/filings/0000318154-25-000072.md) | not reported | [3.34](/filings/0000318154-26-000057.md) | [4.37](/filings/0000318154-26-000126.md) |
| Basic EPS | $ per share | [3.23](/filings/0000318154-24-000044.md) | not reported | [(0.21)](/filings/0000318154-25-000020.md) | [1.39](/filings/0000318154-25-000056.md) | [5.27](/filings/0000318154-25-000072.md) | not reported | [3.22](/filings/0000318154-26-000057.md) | [2.66](/filings/0000318154-26-000126.md) | [5.98](/filings/0000318154-25-000072.md) | not reported | [3.37](/filings/0000318154-26-000057.md) | [4.40](/filings/0000318154-26-000126.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [34.7](/filings/0000318154-23-000064.md) | [10.9](/filings/0000318154-25-000010.md) | [9.7](/filings/0000318154-24-000020.md) | [9.3](/filings/0000318154-24-000035.md) | [9.0](/filings/0000318154-24-000044.md) | [12.0](/filings/0000318154-26-000010.md) | [8.8](/filings/0000318154-25-000020.md) | [8.0](/filings/0000318154-25-000056.md) | [9.4](/filings/0000318154-25-000072.md) | [9.1](/filings/0000318154-26-000126.md) | [12.0](/filings/0000318154-26-000057.md) | [14.0](/filings/0000318154-26-000126.md) |
| Current assets | $bn | [48.5](/filings/0000318154-23-000064.md) | [30.3](/filings/0000318154-25-000010.md) | [28.0](/filings/0000318154-24-000020.md) | [27.2](/filings/0000318154-24-000035.md) | [26.8](/filings/0000318154-24-000044.md) | [29.0](/filings/0000318154-26-000010.md) | [26.9](/filings/0000318154-25-000020.md) | [26.7](/filings/0000318154-25-000056.md) | [27.9](/filings/0000318154-25-000072.md) | [29.1](/filings/0000318154-26-000126.md) | [31.5](/filings/0000318154-26-000057.md) | [35.0](/filings/0000318154-26-000126.md) |
| Total assets | $bn | [90.5](/filings/0000318154-23-000064.md) | [97.2](/filings/0000318154-25-000010.md) | [93.0](/filings/0000318154-24-000020.md) | [90.9](/filings/0000318154-24-000035.md) | [90.9](/filings/0000318154-24-000044.md) | [91.8](/filings/0000318154-26-000010.md) | [89.4](/filings/0000318154-25-000020.md) | [87.9](/filings/0000318154-25-000056.md) | [90.1](/filings/0000318154-25-000072.md) | [90.6](/filings/0000318154-26-000126.md) | [92.5](/filings/0000318154-26-000057.md) | [95.6](/filings/0000318154-26-000126.md) |
| Current liabilities | $bn | [17.0](/filings/0000318154-23-000064.md) | [18.4](/filings/0000318154-25-000010.md) | [19.7](/filings/0000318154-24-000020.md) | [21.5](/filings/0000318154-24-000035.md) | [20.3](/filings/0000318154-24-000044.md) | [23.1](/filings/0000318154-26-000010.md) | [23.0](/filings/0000318154-25-000020.md) | [20.5](/filings/0000318154-25-000056.md) | [21.8](/filings/0000318154-25-000072.md) | [25.5](/filings/0000318154-26-000126.md) | [25.0](/filings/0000318154-26-000057.md) | [25.5](/filings/0000318154-26-000126.md) |
| Long-term debt | $bn | [59.0](/filings/0000318154-23-000064.md) | [63.2](/filings/0000318154-25-000010.md) | [60.1](/filings/0000318154-24-000020.md) | [57.1](/filings/0000318154-24-000035.md) | [56.9](/filings/0000318154-24-000044.md) | [56.5](/filings/0000318154-26-000010.md) | [54.0](/filings/0000318154-25-000020.md) | [53.8](/filings/0000318154-25-000056.md) | [52.4](/filings/0000318154-25-000072.md) | [50.0](/filings/0000318154-26-000126.md) | [51.9](/filings/0000318154-26-000057.md) | [51.9](/filings/0000318154-26-000126.md) |
| Current portion of debt | $bn | [1.4](/filings/0000318154-23-000064.md) | [1.4](/filings/0000318154-25-000010.md) | [4.0](/filings/0000318154-24-000020.md) | [5.5](/filings/0000318154-24-000035.md) | [3.5](/filings/0000318154-24-000044.md) | [3.6](/filings/0000318154-26-000010.md) | [3.4](/filings/0000318154-25-000020.md) | [2.4](/filings/0000318154-25-000056.md) | [2.2](/filings/0000318154-25-000072.md) | [4.6](/filings/0000318154-26-000126.md) | [5.4](/filings/0000318154-26-000057.md) | [5.4](/filings/0000318154-26-000126.md) |
| Short-term borrowings | $bn | not reported | [0.0](/filings/0000318154-25-000010.md) | not reported | not reported | not reported | [0.0](/filings/0000318154-26-000010.md) | not reported | not reported | not reported | [0.0](/filings/0000318154-26-000010.md) | not reported | not reported |
| Shareholders' equity | $bn | [7.7](/filings/0000318154-24-000044.md) | [6.2](/filings/0000318154-26-000010.md) | [5.0](/filings/0000318154-25-000056.md) | [5.9](/filings/0000318154-25-000072.md) | [7.5](/filings/0000318154-25-000072.md) | [5.9](/filings/0000318154-26-000126.md) | [6.2](/filings/0000318154-26-000126.md) | [7.4](/filings/0000318154-26-000126.md) | [9.6](/filings/0000318154-25-000072.md) | [8.7](/filings/0000318154-26-000126.md) | [9.2](/filings/0000318154-26-000126.md) | [11.7](/filings/0000318154-26-000126.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:CommercialPaper
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [2,760 d](/filings/0000318154-24-000044.md) | [538 d](/filings/0000318154-26-000010.md) | [689](/filings/0000318154-25-000020.md) | [2,459 d](/filings/0000318154-25-000056.md) | [3,571 d](/filings/0000318154-25-000072.md) | [4,771 d](/filings/0000318154-26-000010.md) | [1,391](/filings/0000318154-26-000057.md) | [2,280 d](/filings/0000318154-26-000126.md) | [4,684 d](/filings/0000318154-25-000072.md) | [1,603 d](/filings/0000318154-26-000010.md) | [2,189](/filings/0000318154-26-000057.md) | [4,002 d](/filings/0000318154-26-000126.md) |
| Capital expenditure | $m | [248 d](/filings/0000318154-24-000044.md) | [249 d](/filings/0000318154-26-000010.md) | [230](/filings/0000318154-25-000020.md) | [238 d](/filings/0000318154-25-000056.md) | [257 d](/filings/0000318154-25-000072.md) | [371 d](/filings/0000318154-26-000010.md) | [411](/filings/0000318154-26-000057.md) | [369 d](/filings/0000318154-26-000126.md) | [436 d](/filings/0000318154-25-000072.md) | [642 d](/filings/0000318154-26-000010.md) | [712](/filings/0000318154-26-000057.md) | [513 d](/filings/0000318154-26-000126.md) |
| Dividends paid | $m | [1,140 d](/filings/0000318154-24-000044.md) | [1,140 d](/filings/0000318154-26-000010.md) | [1,208](/filings/0000318154-25-000020.md) | [1,209 d](/filings/0000318154-25-000056.md) | [1,210 d](/filings/0000318154-25-000072.md) | [1,205 d](/filings/0000318154-26-000010.md) | [1,279](/filings/0000318154-26-000057.md) | [1,280 d](/filings/0000318154-26-000126.md) | [1,282 d](/filings/0000318154-25-000072.md) | [1,283 d](/filings/0000318154-26-000010.md) | [1,358](/filings/0000318154-26-000057.md) | [1,362 d](/filings/0000318154-26-000126.md) |
| Share repurchases | $m | [0.0 d](/filings/0000318154-23-000064.md) | [0.0 d](/filings/0000318154-26-000010.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [538](/filings/0000318154-23-000064.md) | [538](/filings/0000318154-24-000020.md) | [537](/filings/0000318154-24-000035.md) | [538](/filings/0000318154-24-000044.md) | [536](/filings/0000318154-25-000020.md) | [541](/filings/0000318154-25-000056.md) | [542](/filings/0000318154-25-000072.md) | [541](/filings/0000318154-26-000057.md) | [541](/filings/0000318154-26-000126.md) | [542](/filings/0000318154-25-000072.md) | [544](/filings/0000318154-26-000057.md) | [544](/filings/0000318154-26-000126.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 540,632,005 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0000318154-26-000126.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.